Pre- and post- operative adjuvant targeting locoregional chemotherapy combined with locoregional targeting immunostimulation and surgical resection for hepatocellular carcinoma. A new promising alternative.

Hepatocellular carcinoma remains a challenging disease with a poor prognosis in terms of outcome and overall survival. Although resectional liver surgery remains the optimal treatment option, it is associated with a high incidence of intrahepatic recurrence. We present our experience of a new multimodality treatment approach for the management of patients with hepatocellular carcinoma (HCC), consisting of liver resection in combination with induced targeting locoregional, pre- and post-operative, chemotherapy and immunotherapy in 20 patients with HCC.